Sermorelin Dosage: How It's Used

People searching for a “sermorelin dosage” usually want a number: how much, how often, for how long. This page deliberately doesn’t hand one over — not to be evasive, but because for the way most adults actually use sermorelin, a copyable number is the least useful and most misleading part of the picture. What follows is how a sermorelin dose is genuinely decided, why sermorelin is a special case among peptides, and why the protocols circulating online are built on a foundation that doesn’t hold.

The dose that exists — and who it was for

Most peptides sold on the gray market have no human dose at all to anchor to. Sermorelin is different, and that difference is exactly what makes its internet protocols so persuasive — and so misleading.

Sermorelin genuinely was an FDA-approved drug. Under the brand name Geref, it carried two approvals. The first, in 1990, was as a diagnostic agent: a single weight-based injection used as a one-time test of whether the pituitary gland could secrete growth hormone on cue. The second, in 1997, was as a treatment for idiopathic growth hormone deficiency in children with growth failure — a weight-based dose given daily to help kids whose pituitaries were healthy but under-stimulated grow normally. The branded product was withdrawn in 2008 for commercial reasons, not safety ones, which is why sermorelin still has an unusually clean regulatory history.

Here is the problem. Both of those validated doses belong to someone who isn’t the typical buyer. One is a single bolus given once, in a clinic, to answer a diagnostic question. The other is a pediatric treatment dose for a diagnosed deficiency, scaled to a child’s body weight. Neither was ever an adult protocol for better sleep, recovery, body composition, or “anti-aging.” When a website presents a confident sermorelin schedule, it is almost always quietly repurposing a number whose original context — different age, different indication, different goal, sometimes a different route entirely — has been stripped away.

Note: Borrowing a real dose out of its real context doesn’t make it validated for your use. It makes it a number that looks validated. That illusion of legitimacy is precisely why sermorelin protocols feel more trustworthy than, say, a BPC-157 protocol — and why they deserve the same skepticism.

So the honest answer to “what’s the dose?” has two parts. For the diagnostic and pediatric uses the FDA evaluated, a dose was established — but you are almost certainly not in either of those populations. For the adult wellness use people actually want, no universal validated dose exists, and the evidence base for those uses is graded modestly. (The deeper evidence story sits in the sermorelin benefits and anti-aging pages.)

How a sermorelin dose is actually determined

Strip away the internet charts and a legitimate sermorelin dose is a clinical decision, individualized to one person and adjusted over time. The inputs a prescriber weighs include:

• Baseline labs. IGF-1 is the standard surrogate marker, read against your age-specific reference range rather than a single “optimal” target. A 25-year-old and a 65-year-old with the same IGF-1 number are in very different places.
• The goal. Sleep quality, recovery, and gradual body-composition change are different aims with different realistic timeframes, and they shape both the dose and how success is judged.
• Your physiology. Age, sex, body weight, baseline pituitary function, and any history of conditions affecting growth hormone signaling all matter.
• Response and tolerance over time. Dosing is titrated — nudged based on follow-up labs and how you actually respond — not set once and forgotten.

None of those inputs is available to a website. That’s the structural reason a generic protocol can’t be right for you: it can’t see your labs, your age, or your response, which are the variables that determine the dose in the first place.

Why “more” doesn’t simply mean “more”

Sermorelin’s mechanism builds a ceiling into the dose question that a lot of peptides don’t have. It’s an analog of growth hormone-releasing hormone (GHRH), so it works upstream — it asks the pituitary to release its own growth hormone, rather than flooding the bloodstream with growth hormone directly the way injected HGH does.

Crucially, that means the body’s own negative-feedback brake stays intact. As growth hormone and IGF-1 rise, somatostatin — the hormone that tells the pituitary to ease off — rises too, damping the response. The system self-limits. This is the exact feature marketers cite when they call sermorelin “more physiological” or “safer” than HGH, and they’re not wrong about the mechanism.

But the same feature defeats the logic behind escalating internet ladders. Because the pituitary governs its own output, pushing the dose higher doesn’t translate into a proportionally bigger growth hormone response. Past a point, additional dose tends to add cost, add side-effect risk, and add receptor desensitization faster than it adds any benefit. The thing that makes sermorelin gentle is the same thing that makes “just take more” a poor strategy. A bigger biochemical pulse is also, at best, a surrogate — a lab marker moving, not a proven real-world outcome.

This is also why timing gets discussed more than dose for GHRH analogs. Growth hormone is released in pulses, with the largest naturally occurring in early sleep, and a GHRH analog is meant to amplify that existing rhythm. That makes when relative to the body’s own cycle a genuine clinical variable — and a further reason that a bare milligram figure, divorced from timing and from your physiology, is an incomplete way to think about sermorelin. (It is not, to be clear, a do-it-yourself timing recipe; it’s context a prescriber weighs.)

Why fixed internet protocols are unsafe

Even setting aside the wrong-population problem, a copied protocol fails on a more basic point: a dose is only meaningful if you know what’s in the vial.

Sermorelin sold through “research use only” channels is of unverified concentration and purity. A number that would be reasonable for a pharmacy-grade, accurately labeled product can deliver far more or far less than intended when the actual contents are unknown. This is the core hazard the dosage question keeps colliding with: the right dose of the wrong or unverified product is still the wrong dose. No protocol, however carefully written, can fix a vial whose real contents you can’t confirm.

Layer on the absence of monitoring. The single clearest warning sign in this whole space is a setup that offers a dose without an evaluation — a chart next to a buy button, a quiz-only intake with no labs, a “standard protocol” handed to anyone regardless of their baseline. Legitimate sermorelin care looks like the opposite: baseline IGF-1 and a screen for any active malignancy (because raising growth hormone and IGF-1 signaling carries a theoretical concern around existing tumors), a realistic timeframe, and follow-up labs to see how you’re actually responding. If no one is checking, no one is catching the things a dose is supposed to be adjusted around.

The part that’s genuinely different: a legitimate route exists right now

For many gray-market peptides, telling someone “just get a prescription instead” is almost theoretical — there’s no clean legal compounding channel to point them to. Sermorelin is the rare exception, and it changes the whole calculus of the dosing question.

Sermorelin was never placed on the FDA’s restricted Category 2 list. It sits outside the 2026 reclassification process entirely — the peptides removed from Category 2 around April 2026, and the advisory-committee review scheduled for July 23–24, 2026, concern other compounds; sermorelin’s compounding door was already open and stayed open. (Removal from a restricted list is not the same as FDA approval, and sermorelin is not an FDA-approved finished product today — that’s all covered in the reclassification and legality pages.) It can be compounded by a licensed 503A or 503B pharmacy with a valid prescription in all 50 states.

The practical upshot: you do not need to copy an internet number to access sermorelin. A real prescriber can set a real, monitored dose through a legal channel — which is both safer and, given everything above, the only way to get a dose that’s actually matched to you. Worth knowing for 2026: documentation and clinical-necessity expectations for compounded sermorelin have tightened this year, so prescribers increasingly need to record why the therapy is appropriate and back it with labs. That’s a feature, not an obstacle — it’s the monitoring that a copied protocol skips entirely. (Regulatory specifics here are current as of this page’s date and can change; the prescription page covers the mechanics.)

A note on tested athletes

If you compete under anti-doping rules, the dose discussion is moot: sermorelin is a GHRH analog and falls under WADA’s prohibited peptide-hormone category at all times, in and out of competition. No protocol makes it permitted, and a therapeutic-use exemption for an off-label wellness purpose is a high bar.

The takeaway

Sermorelin is unusual: it has a real FDA dosing history and a real legal route today. Both facts make a copied internet dose more tempting and no more correct. The validated doses were for a diagnostic test and for children with growth failure; the adult wellness dose is an individualized clinical decision built from your labs, age, goals, and response — exactly the inputs a website can’t see. The mechanism caps what extra dose buys you, an unverified vial makes any number unreliable, and a legitimate prescriber-set dose is genuinely within reach. The number, in other words, is the part you should worry about least and outsource to a clinician — not the part you copy from a stranger.

For where to go next: the prescription page covers how a script is written and filled, how to get sermorelin compares the legal routes, sermorelin side effects covers tolerability, and sermorelin vs CJC-1295 compares the two GHRH-path options.